title: Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
abstract: Several studies have suggested risk factors for poor survival in stage IB non-small-cell lung cancer (NSCLC) patients. However, these factors are not definite indicators of adjuvant chemotherapy for stage IB cancer, and most of them can be used to consider adjuvant chemotherapy. We aimed to determine the clinicopathologic factors and assess whether c-MET is a prognostic factor in stage IB NSCLC patients who have undergone surgery. Additionally, we determined the relevance of the factors and the recurrence pattern in these patients.
  
  
  
  This study included 115 patients who underwent resection of pathologic stage IB NSCLC between January 2005 and December 2013. We retrospectively reviewed the clinicopathologic data and performed immunohistochemical analysis for c-MET. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated according to clinicopathologic factors and c-MET expression.
  
  
  
  Lymphovascular invasion (LVI) and c-MET overexpression were significantly associated with poor RFS. A large tumor with visceral pleural invasion (VPI) or LVI, moderate/poor differentiation with LVI, and VPI with LVI were negative prognostic factors for RFS and CSS. c-MET overexpression with a large tumor, VPI, or LVI was an independent prognostic factor for poor RFS and CSS, and LVI was a significant factor for distant recurrence.
  
  
  
  LVI and c-MET overexpression might be associated with poor prognosis in stage IB NSCLC patients. Additionally, survival might be poor in stage IB patients with multiple pathologic risk factors. Moreover, there is a high possibility of distant recurrence in patients with LVI.
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
authors.forename: In Hee
authors.initials: IH
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
authors.forename: Ji Eun
authors.initials: JE
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
authors.forename: Sook Hee
authors.initials: SH
authors.lastname: Hong
authors.affiliation: Department of Pathology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Tae-Jung
authors.initials: TJ
authors.lastname: Kim
authors.affiliation: Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Kyo-Young
authors.initials: KY
authors.lastname: Lee
authors.affiliation: Department of Pulmonology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Young Kyoon
authors.initials: YK
authors.lastname: Kim
authors.affiliation: Department of Pulmonology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Seung Joon
authors.initials: SJ
authors.lastname: Kim
authors.affiliation: Department of Thoracic Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Sook Whan
authors.initials: SW
authors.lastname: Sung
authors.affiliation: Department of Thoracic Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Jae Kil
authors.initials: JK
authors.lastname: Park
authors.affiliation: Department of Nuclear Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Ie Ryung
authors.initials: IR
authors.lastname: Yoo
authors.affiliation: Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
authors.forename: Yeon Sil
authors.initials: YS
authors.lastname: Kim
authors.affiliation: Department of Biomedical Sciences, The Catholic University of Korea, Seoul, Korea.
authors.forename: Jung-Oh
authors.initials: JO
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea. Electronic address: jinkang@catholic.ac.kr.
authors.forename: Jin Hyoung
authors.initials: JH
authors.lastname: Kang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010994:Pleura / Q000473:pathology*; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D019859:Proto-Oncogene Proteins c-met
keywords: NSCLC; Prognosis; Recurrence; Risk factors; c-Met proteins